RHO and cancer: Although the selectivity and potency of adhibin provide significant progress towards biologically active small molecule effectors that target Rho-signalling pathways for use in cancer therapy, a limitation of this study is whether adhibin would exhibit its anti-migratory and anti-adhesive properties observed in the various cancer cell models also in the animal tumour model to act as an anti-metastatic drug.